Vaccine Developer ,Manufacturer                            ,Manufacturer Type     ,Manufacturer Location,Income Level2      ,Anticipated Production Dose/Year (in millions),Anticipated Production Total Doses (in millions),Date Arrangement Publicly Announced,Part of Combination Procurement Arrangement,Government Sponsored/Supported,Arrangement Category     ,Arrangement Details                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ,Associated upgrades/technology transfer details                                                                                                                                                                                                                                                                                                                                                            ,Financing Details                                                                                                                                                                                                                                                                                                                                                                                                                                                                ,Primary Market Intended For,Income Level3      ,Secondary Market         ,Income Level4      ,Notes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ,Sources
AstraZeneca/Oxford,JCR Pharma                              ,Publicly traded       ,Japan                ,High income        ,                                              ,90                                              ,12/1/2020                          ,Yes                                        ,Japan                         ,Bulk substance production,Subcontracted with Daiichi Sankyo and Meiji (drugmakers) for fill-and-finish.                                                                                                                                                                                                                                                                                                                                                                                                                                                              ,"As part of condition of government grant to expand vaccine production capacity, will build additional facility in Japan, to be completed by October 2022.                                                                                                                                                                                                                                                ",Supported by Japanese government grant. Company will invest 108.28 USD to build new facility.                                                                                                                                                                                                                                                                                                                                                                                    ,Japan                      ,High income        ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.channelnewsasia.com/news/asia/japan-jcr-pharma-build-new-plant-covid-19-vaccine-14332146 ; https://asia.nikkei.com/Spotlight/Coronavirus/Japan-to-produce-90m-doses-of-AstraZeneca-COVID-19-vaccine
AstraZeneca/Oxford,Fiocruz                                 ,State-owned enterprise,Brazil               ,Upper middle income,200                                           ,                                                ,6/30/2020                          ,Yes                                        ,Brazil                        ,Phased full process      ,"Fiocruz will initially fill and finish the active ingredients sent to Brazil, and is eventually aiming to produce it entirely                                                                                                                                                                                                                                                                                                                                                                                                            ","AstraZeneca will transfer all relevant tech, API, and know-how before July 2021                                                                                                                                                                                                                                                                                                                          ","Varies by source. Approximately 348 million USD is predicted by the Brazilian MoH to be transferred. 98.2m for vaccine processing; 244.4m for technology, including API receipt and tech transfer; and 16.1m for adaptations to the ""productive and quality control areas"". Other sources put the cost at 360m to cover both purchase of 100m doses and the licensing rights. Vaccine cost 3.16 USD/dose.                                                                    ",Brazil                     ,Upper middle income,                         ,#N/A               ,"Before July 2021 100.4 m doses will be produced; up until that point, neither side is allowed to introduce profit margins. After that, Fiocruz is anticipated to be capable of indepenently manufacturing the vaccine. COPY OF CONTRACT AVAILABLE. In Jan 2021, there are reports of unexpected delays with the tech tranfer/Fiocruz not being able to produce vaccines as quickly as had been expected.                                                                                                                                                        ",https://www.fiotec.fiocruz.br/en/news/7233-fiocruz-and-astrazeneca-align-details-to-produce-a-vaccine-for-covid-19 ; https://portal.fiocruz.br/en/news/covid-19-vaccine-fiocruz-discloses-its-technological-order-agreement-astrazeneca ; https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/u34/contrato_etec.pdf; https://www.fiercepharma.com/manufacturing/astrazeneca-bumps-up-vaccine-deal-brazil-to-360m-more-doses-licensing-rights
AstraZeneca/Oxford,Shenzhen Kangtai                        ,Publicly traded       ,China                ,Upper middle income,400                                           ,                                                ,8/6/2020                           ,No                                         ,                              ,Full process             ,"Shenzhen Kangtai guaranteeing production of 100m by end of 2020 and 200m/year at least by end of 2021. Under terms, manufacturer will have exclusive rights to conduct clinical trials of the candidate in China.                                                                                                                                                                                                                                                                                                                        ","AstraZeneca to provide tech transfer to ""develop, produce, and commercialize"" the product in China.                                                                                                                                                                                                                                                                                                    ",                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,China                      ,Upper middle income,                         ,#N/A               ,"The facility, as of Feb 2021, has been expanded to double its capacity, and will be able to produce up to 400m doses per year. Exclusive deal with Shenzhen Kangtai to supply the AstraZeneca vaccine to Chinese market. Questions raised about viability of deal, given that it is unclear whether China will accept foreign clinical trial results and there are not enough cases to complete trials in China at this time.                                                                                                                                   ",https://www.reuters.com/article/us-health-coronavirus-kangtai-astrazenec-idUSKBN2A20VB; https://www.bioworld.com/articles/496620-astrazeneca-partners-with-kangtai-bio-to-bring-covid-19-vaccine-to-china ; https://www.reuters.com/article/health-coronavirus-astrazeneca-kangtai-b/astrazeneca-in-deal-with-kangtai-bio-to-supply-potential-covid-19-vaccine-in-china-idUSL4N2F82BI?edition-redirect=uk ; https://www.nytimes.com/2020/12/07/business/china-vaccine-astrazeneca.html
AstraZeneca/Oxford,Serum Institute                         ,Publicly traded       ,India                ,Lower middle income,1000                                          ,                                                ,6/4/2020                           ,No                                         ,                              ,Full process             ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,"Licensing agreement, limited information on tech transfer                                                                                                                                                                                                                                                                                                                                                ",                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,World                      ,0                  ,India                    ,Lower middle income,"The original agreement was to supply one billion doses for low-and-middle-income countries, with 400m before end of 2020. Unclear what proportion of this will be for use in India versus available to other LMICs, however the Serum Institute has stated that half of all vaccines manufactured by it will be reserved for the domestic market.                                                                                                                                                                                                               ",https://www.astrazeneca.com/media-centre/articles/2020/astrazeneca-takes-next-steps-towards-broad-and-equitable-access-to-oxford-universitys-potential-covid-19-vaccine.html
AstraZeneca/Oxford,Siam Bioscience                         ,Privately held        ,Thailand             ,Upper middle income,                                              ,200                                             ,10/27/2020                         ,Yes                                        ,Thailand                      ,Bulk substance production,"Arrangement signed to enable large scale manufacturing at Siam Bioscience and supply of the vaccine in South East Asia through technology transfer. A letter of intent signed between the Ministry of Public Health (Thailand), SCG, Siam Bioscience and AstraZeneca.                                                                                                                                                                                                                                                                    ","The press releases for the deal mention 'technology transfer' without any specific details, focusing on increasing global manufacturing capacities.                                                                                                                                                                                                                                                      ",About $16.7m support from the government and $3.3m from SCG                                                                                                                                                                                                                                                                                                                                                                                                                      ,                           ,#N/A               ,                         ,#N/A               ,"Intended for South-East Asia market. More than half of the anticipated 200m doses are expected to be exported, with only 26m doses supposedly reserved for Thailand.                                                                                                                                                                                                                                                                                                                                                                                            ",
AstraZeneca/Oxford,IRBM                                    ,Privately held        ,Italy                ,High income        ,                                              ,70                                              ,5/28/2020                          ,No                                         ,                              ,Full process             ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.reuters.com/article/uk-health-coronavirus-italy-vaccine/italy-set-for-16-million-astrazeneca-covid-19-shots-in-early-2021-source-idUKKBN2841KY ; https://www.advent-gmp.com/news/irbms-advent-announces-manufacture-of-13000-doses-of-covid-19-vaccine-for-use-in-phase-2-3-clinical-trials-by-the-university-of-oxford/
AstraZeneca/Oxford,mAbxience                               ,Privately held        ,Spain                ,High income        ,200                                           ,                                                ,8/17/2020                          ,No                                         ,                              ,Full process             ,"Arrangement signed to manufacture active ingredient in Argentina, then complete production and filling at a plant in Mexico. To produce at least 200m doses for Latin America (excluding Brazil). Option to increase to 400 m. Funded by Carlos Slim Foundation.                                                                                                                                                                                                                                                                         ",N/A                                                                                                                                                                                                                                                                                                                                                                                                        ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Latin America & Caribbean  ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.mabxience.com/mabxience-enters-into-an-agreement-with-astrazeneca-to-produce-covid-19-vaccine/; https://www.aljazeera.com/news/2020/08/mexico-signs-covid-19-vaccine-deal-cases-top-500000-200814061708568.html ;  https://s3.amazonaws.com/one.org/vaccine-access-test/ONE_VAT_deal_AstraZeneca_Latin_America_Mexico_Argentina.pdf
AstraZeneca/Oxford,Halix                                   ,Privately held        ,Netherlands          ,High income        ,                                              ,                                                ,12/8/2020                          ,No                                         ,                              ,Full process             ,"To provide ""commercial manufacturing of drug substance"" at its cGMP facility in the Netherlands.                                                                                                                                                                                                                                                                                                                                                                                                                                       ",It is adding two additional viral vector production lines to meet demand.                                                                                                                                                                                                                                                                                                                                  ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.halix.nl/2020/12/08/halix-signs-agreement-astrazeneca-commercial-manufacture-covid-19-vaccine/
AstraZeneca/Oxford,Oxford Biomedica                        ,Publicly traded       ,United Kingdom       ,High income        ,                                              ,                                                ,9/1/2020                           ,No                                         ,United Kingdom                ,Full process             ,"18-month supply agreement, as part of a 3 year Master Supply and Development Agreement for ""large-scale commercial manufacture"" of the vaccine candidate. Will be produced at a facility with a up to 1,000L scale                                                                                                                                                                                                                                                                                                                     ",                                                                                                                                                                                                                                                                                                                                                                                                           ,"AZ will pay Oxford Biomedica 15m GBP upfront as a ""capacity reservation fee"". Oxford Biomedica ""will reserve capacity for AstraZeneca in up to three manufacturing sites.""                                                                                                                                                                                                                                                                                                 ",United Kingdom             ,High income        ,World                    ,0                  ,"United Kingdom does not appear to be a direct party to this arrangement, but Oxford Biomedica is part of a separate arrangement with the UK government, via the Vaccines Manufacturing Innovation Centre, which is intended to be used ""by UK authorities to  manufacture vaccines rapidly in the event of a future pandemic."" Through this arrangement, Oxford Biomedica received funding to speed up development of two new manufacturing suites.                                                                                                           ",https://www.oxb.com/news-media/press-release/oxford-biomedica-signs-supply-agreement-astrazeneca-expand-manufacturing
AstraZeneca/Oxford,"Albany Molecular Research, Inc (AMRI) ",Publicly traded       ,United States        ,High income        ,                                              ,                                                ,9/3/2020                           ,No                                         ,United States                 ,Fill-and-finish          ,"AMRI will provide fill-and-finish through its plant in New Mexico; potential to ""produce millions of doses of AZD1222 annually"".                                                                                                                                                                                                                                                                                                                                                                                                       ",Plans to add approximately 150 employees at its New Mexico plant to meet production demands.                                                                                                                                                                                                                                                                                                               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,"US not a direct party to the arrangement, but BARDA appears to have provided the funding to AstraZeneca to seek out this manufacturing arrangement.                                                                                                                                                                                                                                                                                                                                                                                                             ",https://www.amriglobal.com/blog/news-and-events/news/amri-selected-to-support-astrazeneca-in-delivery-of-covid-19-vaccine/ ; https://www.bizjournals.com/albuquerque/news/2020/09/18/abq-manufacturer-to-play-a-role-in-covid-vaccine.html
AstraZeneca/Oxford,Catalent                                ,Publicly traded       ,United States        ,High income        ,                                              ,                                                ,6/1/2020                           ,No                                         ,                              ,Full process             ,"A Catalent plant in the US will produce the drug substance, and Catalent's facility in Italy will provide ""large-scale vial filling and packaging"". The contract with the Italy plant preceded the US plant.                                                                                                                                                                                                                                                                                                                           ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,"Italy refused in Mar 2021 to export doses made at the Catalent plant in Italy to Australia, citing underdelivery of AZ vaccine in EU.                                                                                                                                                                                                                                                                                                                                                                                                                           ",https://www.dw.com/en/eu-blocks-export-of-astrazeneca-covid-19-vaccines-to-australia/a-56774362 ; https://www.catalent.com/catalent-news/catalent-signs-agreement-with-astrazeneca-to-expand-manufacturing-support-for-covid-19-vaccine-azd1222/
AstraZeneca/Oxford,Emergent BioSolutions                   ,Publicly traded       ,United States        ,High income        ,                                              ,                                                ,6/11/2020                          ,No                                         ,United States                 ,Full process             ,"Emergent will provide ""molecule-to-market contract development and manufacturing services"" and ""provide development services, technology transfer, analytical testing, drug substance process and performance qualification and will reserve large-scale manufacturing capacity through 2020."" Scaling up to 4000L manufacturing capacity; with capacity to produce ""tens to hundreds of millions of doses of vaccine on an annual basis"".                                                                                         ",                                                                                                                                                                                                                                                                                                                                                                                                           ,Deal valued at approximately 87m USD. Funded by US government Operation Warp Speed.                                                                                                                                                                                                                                                                                                                                                                                              ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-agreement-be-us-manufacturing-0?field_nir_news_date_value%5Bmin%5D=
AstraZeneca/Oxford,Cobra Biologics                         ,Privately held        ,United States        ,High income        ,                                              ,                                                ,6/16/2020                          ,No                                         ,                              ,Full process             ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,"Cobra has US headquarters, but plants in the UK and Sweden.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ",https://www.cobrabio.com/news/june-2020/cobra-supply-agreement-astrazeneca-covid19-vaccine
AstraZeneca/Oxford,Novasep                                 ,Publicly traded       ,France               ,High income        ,                                              ,                                                ,6/14/2020                          ,No                                         ,European Union                ,Bulk substance production,"Initial contract signed in June 2020 ""in the context of the Inclusive Alliance for Vaccines, whose members are France, Germany, Italy and the Netherlands."" A new contract was signed in November 2020 - a multi-year Master Supply and Development Agreement. Under agreement, Novasep will be producing the vaccine candidate active substance at its plant in Belgium.                                                                                                                                                              ",Will increase workforce from 280 to 400 by 2021.                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,European Union             ,High income        ,                         ,#N/A               ,Not clear to what extent EU is involved with this arrangement. AZ attributed delays in EU deliveries to the Novasep factory in Jan 2021.                                                                                                                                                                                                                                                                                                                                                                                                                          ,https://www.theguardian.com/world/2021/jan/22/covid-oxfordastrazeneca-vaccine-delivery-to-eu-to-be-cut-by-60 ; https://www.novasep.com/home/about-novasep/media-events/press-release/covid-19-vaccine-candidate-novasep-signs-a-master-supply-and-development-agreement-with-astrazeneca.html
AstraZeneca/Oxford,IDT Biologika                           ,Privately held        ,Germany              ,High income        ,                                              ,                                                ,2/10/2021                          ,No                                         ,Germany                       ,Phased full process      ,"AstraZeneca and IDT Biologika are exploring options to accelerate output of finished vaccine, and for bulk production of other vaccines in the future.                                                                                                                                                                                                                                                                                                                                                                                   ",                                                                                                                                                                                                                                                                                                                                                                                                           ,"Both companies plan to invest in capacity expansion at IDT Biologika’s production site in Dessau, Germany to build up to five 2,000L bioreactors capable of making tens of millions of doses per month of AstraZeneca’s COVID-19 vaccine. The new assets are estimated to be operational by the end of 2022. IDT will invest hundreds of millions of euros in this expansion                                                                                                   ",European Union             ,High income        ,                         ,#N/A               ,German government credited in the announcement for its support in reaching the agreement.                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ,https://idt-biologika.com/assets/uploads/downloads/presse/2021/210210_IDT_AstraZeneca_en.pdf ; https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/astrazeneca-and-idt-biologika-sign-letter-of-intent-to-increase-covid-19-vaccine-manufacturing-in-europe-and-secure-long-term-supply-capacity.html
AstraZeneca/Oxford,CSL                                     ,Publicly traded       ,Australia            ,High income        ,                                              ,50                                              ,7/9/2020                           ,Yes                                        ,Australia                     ,Full process             ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Australia                  ,High income        ,                         ,#N/A               ,An additional 3.8m doses will be purchased directly.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              ,https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/about-covid-19-vaccines/australias-vaccine-agreements; https://www.theguardian.com/australia-news/2020/sep/06/australian-government-announces-covid-vaccine-deals-to-provide-848m-doses; https://www.abc.net.au/news/2020-08-18/australia-locks-in-oxford-astrazeneca-coronavirus-vaccine-deal/12571454 ; https://s3.amazonaws.com/one.org/vaccine-access-test/ONE_VAT_deal_AstraZeneca_Australia.pdf
AstraZeneca/Oxford,Wockhardt                               ,Publicly traded       ,India                ,Lower middle income,                                              ,                                                ,8/2/2020                           ,No                                         ,United Kingdom                ,Fill-and-finish          ,"The agreement is with the UK govt for fill and finish at the company's UK sites. The manufacturer is capable of producing ""millions"" of doses but it is unclear how many or on what timeline                                                                                                                                                                                                                                                                                                                                           ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,United Kingdom             ,High income        ,                         ,#N/A               ,"The actual partnership is with the UK govt, which gave an 18 month contract to fill and finish vials in the UK facilities through its subsidiary CP Pharmaceuticals. AstraZeneca is one of the vaccines the manufacturer can fill and finish. The pharma has also offered its plants in India.                                                                                                                                                                                                                                                                  ",https://www.wockhardt.co.uk/about-wockhardt/wockhardt-news/wockhardt-announces-covid-19-vaccine-partnership-with-uk-government.aspx
AstraZeneca/Oxford,R-Pharm                                 ,Privately held        ,Russian Federation   ,Upper middle income,                                              ,                                                ,7/17/2020                          ,No                                         ,                              ,Full process             ,Agreement to produce vaccine at manufacturer's facility in Germany.                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,World                    ,0                  ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.dw.com/en/astrazeneca-covid-vaccine-oxford/a-56427963 ; https://www.reuters.com/article/us-health-coronavirus-cyber-russia-exclu-idUSKCN24I15L
AstraZeneca/Oxford,Insud Pharma                            ,Privately held        ,Spain                ,High income        ,                                              ,                                                ,1/30/2021                          ,No                                         ,                              ,Fill-and-finish          ,Insud will provide vial filling and packaging.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.insudpharma.com/spanish-group-insud-pharma-signs-agreement-astrazeneca-manufacture-covid-19-vaccine-candidate ; https://www.dw.com/en/astrazeneca-covid-vaccine-oxford/a-56427963
AstraZeneca/Oxford,Wuxi Biologics                          ,Publicly traded       ,China                ,Upper middle income,                                              ,                                                ,                                   ,No                                         ,                              ,Bulk substance production,Reuters reports that WuXi is producing AZ doses for supply to Brazil. One report mentions that WuXi produced active ingredients for Fiocruz in its China facility. Other sources mention that WuXi is producing the vaccine at an acquired Bayer facility in Germany.                                                                                                                                                                                                                                                                      ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Brazil                     ,Upper middle income,Unspecified              ,0                  ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.dw.com/en/astrazeneca-covid-vaccine-oxford/a-56427963 ; https://www.reuters.com/article/pfizer-ma-wuxi-bio-cay/wuxi-biologics-says-to-acquire-pfizers-biologic-drug-plant-in-china-idUSL4N2LF0KI ; https://www.plenglish.com/index.php?o=rn&id=64888&SEO=brazil-will-receive-supplies-to-produce-oxfords-covid-19-vaccines ; https://bioprocessintl.com/bioprocess-insider/facilities-capacity/wuxi-to-make-covid-19-vaccine-at-shelved-bayer-hemophilia-drug-plant/
Bharat Biotech    ,Ocugen Inc                              ,Publicly traded       ,United States        ,High income        ,                                              ,                                                ,2/2/2021                           ,No                                         ,                              ,Full process             ,"Bharat and Ocugen will co-develop, supply, and commercialize for the US market. Ocugen will have the US rights and will be responsible for many aspects including clinical development and commercialisation.                                                                                                                                                                                                                                                                                                                            ",Bharat will facilitate tech transfer to help the manufacturing process.                                                                                                                                                                                                                                                                                                                                    ,Ocugen will retain 45% of the profits.                                                                                                                                                                                                                                                                                                                                                                                                                                           ,United States              ,High income        ,                         ,#N/A               ,Ocugen to receive initial supply of COVAXIN™ doses from Bharat Biotech upon authorization from US regulatory authorities while it ramps up manufacturing in the US                                                                                                                                                                                                                                                                                                                                                                                                ,https://www.globenewswire.com/news-release/2021/02/02/2168331/0/en/Ocugen-and-Bharat-Biotech-Announce-Execution-of-Definitive-Agreement-for-the-Commercialization-of-COVAXIN-in-the-US-Market.html
CanSino Biologics ,Drugmex                                 ,Privately held        ,Mexico               ,Upper middle income,                                              ,                                                ,2/1/2021                           ,No                                         ,                              ,Fill-and-finish          ,At least 4m doses are expected to sent to the Drugmex facility in Mexico for fill-and-finish. Unclear if Mexican government is involved in the arrangement.                                                                                                                                                                                                                                                                                                                                                                                ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Mexico                     ,Upper middle income,                         ,#N/A               ,"Drugmex is a Mexican company, but is a subsidiary of an Argentinian company, Grupo Dromex.                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ",https://www.gob.mx/sre/en/articulos/mexico-accelerates-national-vaccination-plan-will-receive-22-million-additional-doses-of-sinovac-and-sinopharm-vaccines-266424
CanSino Biologics ,AJM Pharma Pvt                          ,Privately held        ,Pakistan             ,Lower middle income,                                              ,20                                              ,7/6/2020                           ,Yes                                        ,Pakistan                      ,Fill-and-finish          ,"It is reported that by conducting fill-and-finish in Pakistan, the overall cost of procuring the vaccines will be reduced by 25%.                                                                                                                                                                                                                                                                                                                                                                                                        ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Pakistan                   ,Lower middle income,                         ,#N/A               ,Pakisan government & AJM are running local clinical trials fro CanSino                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            ,https://economictimes.indiatimes.com/small-biz/entrepreneurship/crowdfundings-tryst-with-success/articleshow/81464803.cms ; https://www.dawn.com/news/1568149 ; https://www.bloomberg.com/news/articles/2021-01-22/china-vaccine-maker-cansino-to-offer-pakistan-20-million-doses
CanSino Biologics ,Petrovax                                ,Privately held        ,Russian Federation   ,Upper middle income,120                                           ,                                                ,9/21/2020                          ,No                                         ,                              ,Full process             ,"Will have exclusive rights to sell in Russia and CIS countries if approved in Russia. Conducting clinical trial in Russia. Conflicting information on dose capacity; Petrovax's website said in a September release that it was currently  making 4 m doses/month, and with improvements, could be expanded to make up to 10m doses/month. Petrovax investing 13 million USD to expand production capacity.                                                                                                                              ",Approximately 13m USD being invested to expand manufacturing capacity.                                                                                                                                                                                                                                                                                                                                     ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Russian Federation         ,Upper middle income,                         ,#N/A               ,Secondary market of Eastern European countries within the Commonwealth of Independent States (CIS)                                                                                                                                                                                                                                                                                                                                                                                                                                                                ,https://petrovax.com/press_centre/news/2020/1881/ ; https://www.bnnbloomberg.ca/russia-s-richest-man-seeks-global-market-for-local-covid-19-drug-1.1527470
Curevac           ,Novartis                                ,Publicly traded       ,Switzerland          ,High income        ,50                                            ,250                                             ,3/4/2021                           ,No                                         ,                              ,Bulk substance production,Plans to produce the mRNA and bulk drug product at facility in Austria.                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ,Tech transfer mentioned as part of the agreement.                                                                                                                                                                                                                                                                                                                                                          ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,World                      ,0                  ,                         ,#N/A               ,"50m doses anticipated in 2021, 200m in 2022.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    ",https://www.novartis.com/news/media-releases/novartis-signs-initial-agreement-curevac-manufacture-covid-19-vaccine-candidate
Curevac           ,Fareva                                  ,Privately held        ,France               ,High income        ,                                              ,                                                ,12/9/2020                          ,No                                         ,                              ,Fill-and-finish          ,"Fareva's plants in France will provide fill & finish. This arrangement will support the production of ""millions of doses"".                                                                                                                                                                                                                                                                                                                                                                                                             ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.curevac.com/2020/12/09/curevac-and-fareva-sign-agreement-for-fill-finish-manufacturing-of-curevacs-covid-19-vaccine-candidate-cvncov/
Curevac           ,Bayer                                   ,Publicly traded       ,Germany              ,High income        ,                                              ,                                                ,1/7/2021                           ,No                                         ,                              ,Other                    ,"Through this ""collaboration and services arrangement"" Bayer will support CureVac in ""development and supply of"" the vaccine and will ""facilitate the supply of several hundred million doses."" Curevac will remain the Marketing Authorization Holder, but Bayer ""will support CureVac with country operations within the European Union (EU) and selected additional markets"" and Bayer holds ""further options to become Marketing Authorization Holder in market outside Europe""                                             ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://media.bayer.com/baynews/baynews.nsf/id/CureVac-and-Bayer-join-forces-on-COVID-19-vaccine-candidate-CVnCoV
Curevac           ,GlaxoSmithKline                         ,Publicly traded       ,United Kingdom       ,High income        ,100                                           ,                                                ,2/3/2021                           ,No                                         ,                              ,Full process             ,"GSK and Curevac have agreed to develop ""next generation mRNA vaccines for COVID-19"" and will also support the ""manufacture of up to 100 million doses of CureVac's first generation COVID-19 vaccine candidate"" in 2021.                                                                                                                                                                                                                                                                                                             ",                                                                                                                                                                                                                                                                                                                                                                                                           ,Estimated a 150m GBP collaboration for the development of a new multivalent approach.                                                                                                                                                                                                                                                                                                                                                                                            ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-to-develop-next-generation-mrna-covid-19-vaccines/
Curevac           ,Rentschler Biopharma SE                 ,Privately held        ,Germany              ,High income        ,100                                           ,                                                ,11/1/2020                          ,No                                         ,                              ,Full process             ,"Will manufacture the API, ""downstream processing and formulation of drug substance for the vaccine."" Will be manufactured at Rentschler's site in Laupheim, Germany                                                                                                                                                                                                                                                                                                                                                                    ",Hiring additional 80 workers to meet demand                                                                                                                                                                                                                                                                                                                                                                ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.curevac.com/en/2021/02/01/curevac-and-rentschler-biopharma-ramp-up-manufacturing-of-covid-19-vaccine-cvncov/
Curevac           ,WACKER Chemie AG                        ,Publicly traded       ,Germany              ,High income        ,100                                           ,                                                ,11/23/2020                         ,No                                         ,                              ,Full process             ,Contract development and manufacturing. 100m doses/year to be produced at the WACKER Amsterdam facility.                                                                                                                                                                                                                                                                                                                                                                                                                                   ,Includes tech transfer and may include plant expansion.                                                                                                                                                                                                                                                                                                                                                    ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.curevac.com/en/2020/11/23/curevac-and-wacker-sign-manufacturing-contract-for-curevacs-covid-19-vaccine-candidate-cvncov/
Gamaleya          ,Unidentified                            ,                      ,"Iran, Islamic Rep. ",Upper middle income,40                                            ,                                                ,1/30/2021                          ,Yes                                        ,Iran                          ,Full process             ,"Gamaleya and an unspecified Iranian manufacturer will begin to ""jointly produce"" the vaccine in Iran before March 20, 2021.                                                                                                                                                                                                                                                                                                                                                                                                            ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,"Iran, Islamic Rep.       ",Upper middle income,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.chinadailyasia.com/article/160094 ; https://tass.com/world/1250733 ; https://www.reuters.com/article/health-coronavirus-iran-vaccination-int/iran-starts-covid-vaccination-awaits-more-vaccine-deliveries-idUSKBN2A9120
Gamaleya          ,Belpharprom                             ,State-owned enterprise,Belarus              ,Upper middle income,                                              ,                                                ,11/11/2020                         ,Yes                                        ,Belarus                       ,Full process             ,RDIF has provided the documentation and necessary biological material for the vaccine’s production. RDIF also assisted in equipment selection and procurement of any necessary consumables required in the process.                                                                                                                                                                                                                                                                                                                        ,RDIF has transferred the required vaccine production technology                                                                                                                                                                                                                                                                                                                                            ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Belarus                    ,Upper middle income,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://rdif.ru/Eng_fullNews/6473/ ; https://sputnikvaccine.com/newsroom/pressreleases/belarus-starts-vaccination-with-sputnik-v-/ ; https://www.ft.com/content/ffe40c7d-c418-4a93-a202-5ee996434de7
Gamaleya          ,Dr Reddy's                              ,Publicly traded       ,India                ,Lower middle income,                                              ,100                                             ,9/16/2020                          ,No                                         ,                              ,Other                    ,The two will cooperate on clinical trials and distribution of Sputnik V vaccine in India                                                                                                                                                                                                                                                                                                                                                                                                                                                   ,"Details of tech transfer unavailable, but Dr Reddy's said in Nov 2020 that 'that the process of technology transfer started at its partner site (for manufacturing) in India' (Business Standard)                                                                                                                                                                                                        ",                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,India                      ,Lower middle income,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.prnewswire.com/news-releases/rdif-and-dr-reddys-to-cooperate-on-clinical-trials-and-supply-of-100-million-doses-of-sputnik-v-vaccine-to-india-301132146.html ; https://www.business-standard.com/article/companies/hetero-labs-to-manufacture-100-mn-doses-of-sputnik-v-vaccine-for-india-120112700495_1.html ; https://www.ft.com/content/316b77c1-e640-4d53-8dec-547b1b5651d8
Gamaleya          ,Hetero                                  ,Privately held        ,India                ,Lower middle income,100                                           ,                                                ,11/27/2020                         ,No                                         ,                              ,Full process             ,"Contract to produce ""more than"" 100m doses/year.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,February Financial Times article notes that Hetero is awaiting approval from national regulators before it can begin to growing the bulk virus culture.                                                                                                                                                                                                                                                                                                                                                                                                           ,https://sputnikvaccine.com/newsroom/pressreleases/rdif-and-hetero-agree-to-produce-over-100-million-doses-of-the-sputnik-v-vaccine-in-india/ ; https://www.ft.com/content/316b77c1-e640-4d53-8dec-547b1b5651d8
Gamaleya          ,União Química                           ,Privately held        ,Brazil               ,Upper middle income,72                                            ,                                                ,10/29/2020                         ,No                                         ,                              ,Full process             ,"União Química will locally produce the vaccine for Brazil and other Latin American countries. 72m doses in 2021 anticipated, based on estimate of 8m doses/month being produced starting in April. Technology transfer from RDIF, ""including provision of documents and biomaterials. Local production of Sputnik V in Brazil has been launched in January."" Reporting from February 2021 notes that production at Uniao Quimica was in pilot production and would reach ""full output of 8m doses per month"" starting in April 2021. ","Technology transfer ""including provision of documents and biomaterials. Local prodcution of Sputnik V in Brazil has been launched in January.""                                                                                                                                                                                                                                                         ",                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Brazil                     ,Upper middle income,Latin America & Caribbean,0                  ,União Química plans to make vaccine produced by it available in Brazil and throughout Latin America at ~3 USD/dose.                                                                                                                                                                                                                                                                                                                                                                                                                                               ,https://sputnikvaccine.com/newsroom/pressreleases/rdif-and-uni-o-qu-mica-file-documents-for-registration-of-sputnik-v-vaccine-with-regulator-in-brazil/ ; https://www.reuters.com/article/us-health-coronavirus-brazil-sputnik-idUSKBN2782VS ; https://www.reuters.com/article/us-health-coronavirus-russia-vaccine-bra/russia-makes-preliminary-submission-of-covid-19-vaccine-to-brazil-regulators-idUSKBN27F2OO ; https://sputnikvaccine.com/newsroom/pressreleases/rdif-and-uni-o-qu-mica-to-supply-10-million-doses-of-sputnik-v-vaccine-to-brazil/ ; https://www.ft.com/content/316b77c1-e640-4d53-8dec-547b1b5651d8
Gamaleya          ,VisCoran                                ,Privately held        ,Turkey               ,Upper middle income,                                              ,                                                ,1/23/2021                          ,No                                         ,                              ,Full process             ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,"No details, but mention tech transfer in the press release                                                                                                                                                                                                                                                                                                                                               ",                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Turkey                     ,Upper middle income,Unspecified              ,0                  ,Details are unclear. There are mentions of supplying the Turkish market first before supplying to other countries. Number of doses also not mentioned in the press release.                                                                                                                                                                                                                                                                                                                                                                                       ,https://tass.com/economy/1248149 ; https://ahvalnews.com/sputnik-v/turkish-state-run-bank-chief-lead-production-sputnik-v-head-mystery-pharma-firm
Gamaleya          ,Duopharma Biotech                       ,Publicly traded       ,Malaysia             ,Upper middle income,                                              ,6.4                                             ,1/26/2021                          ,Yes                                        ,Malaysia                      ,Fill-and-finish          ,Duopharma will also distribute the vaccine in Malaysia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ,"RDIF and Gamaleya will provide some technology transfer, but details are vague.                                                                                                                                                                                                                                                                                                                          ",                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Malaysia                   ,Upper middle income,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=111133&name=EA_GA_ATTACHMENTS
Gamaleya          ,Karaganda Pharmaceutical Enterprises    ,Unclear               ,Kazakhstan           ,Upper middle income,                                              ,2                                               ,12/4/2020                          ,No                                         ,Kazakhstan                    ,Bulk substance production,"Kazakhstan is producing the vaccine locally, which will be sent to Gamaleya for final verification. Via a cooperation agreement between RDIF and Kazakhstan Ministry of Health.                                                                                                                                                                                                                                                                                                                                                          ","Tech transfer details are limited, but RDIF news reports that RDIF and the Gamaleya Center are providing any necessary assistance to facilitate technology transfer. The capacity is reported as at least 2m doses.                                                                                                                                                                                      ",                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Kazakhstan                 ,Upper middle income,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://rdif.ru/fullNews/6218/; https://gmpnews.net/2020/12/production-of-russian-sputnik-v-vaccine-against-coronavirus-launched-in-kazakhstan/ ; https://www.themoscowtimes.com/2021/02/16/kazakhstan-to-roll-out-first-locally-produced-sputnik-vaccine-a72971
Gamaleya          ,Richmond Laboratories                   ,Publicly traded       ,Argentina            ,Upper middle income,                                              ,                                                ,2/26/2021                          ,No                                         ,Argentina                     ,Full process             ,"The MoU says that Hetero Biopharmaceuticals (India) will do the tech transfer to Richmond. This agreement was achieved with the participation of both Russian and Argentinean governments, and the ambassador in Russia said that it'll help Argentineans to get the vaccine faster in the long term.                                                                                                                                                                                                                                    ",Richmond Director says that it will take 1 year to do the full tech transfer and start producing the vaccine. Richmond will build a new facility in Argentina to manufacture the vaccine.                                                                                                                                                                                                                  ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Argentina                  ,Upper middle income,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.telesurtv.net/news/argentina-rusia-laboratorio-richmond-producir-sputnikv-20210227-0011.html https://www.elcomercial.com.ar/4925-el-laboratorio-richmond-cerro-un-acuerdo-para-producir-la-sputnik-v-en-la-argentina
Gamaleya          ,Adienne Pharma & Biotech                ,Privately held        ,Switzerland          ,High income        ,                                              ,10                                              ,3/9/2021                           ,No                                         ,                              ,Full process             ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,"Production will take place at the facility in Italy. Details of the arrangement are limited, but mass production is subject to approval in Italy. If vaccine is not approved by July 2021, Russia will buy back the produced doses. The manufacturer is registered in Switzerland but has the manufacturing facility in Italy.                                                                                                                                                                                                                                  ",https://www.swissinfo.ch/eng/swiss-based-pharma-group-to-produce-sputnik-vaccine-in-italy/46433126 ; https://www.reuters.com/article/us-health-coronavirus-russia-italy/doses-of-russias-sputnik-v-made-in-italy-to-go-on-sale-no-sooner-than-late-2021-tass-idUSKBN2B40YI
Gamaleya          ,GL Rapha                                ,Privately held        ,South Korea          ,High income        ,150                                           ,                                                ,11/13/2020                         ,No                                         ,                              ,Full process             ,"GL Rapha intends to supply ""over 150 million doses per year"" for global distribution. Has reported that it does not have capacity on its own to produce that amount, so will be subcontracting production as well as expanding its own facilities.                                                                                                                                                                                                                                                                                     ",Expansion of facilities planned.                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,World                      ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://sputnikvaccine.com/newsroom/pressreleases/rdif-and-gl-rapha-agree-to-produce-over-150-million-doses-of-the-sputnik-v-vaccine-in-south-korea/ ; https://www.ft.com/content/316b77c1-e640-4d53-8dec-547b1b5651d8 ; https://www.reuters.com/article/health-coronavirus-russia-vaccine-idINKBN27T0KO
Gamaleya          ,Tibet Rhodiola Pharma                   ,Publicly traded       ,China                ,Upper middle income,                                              ,40                                              ,11/11/2020                         ,No                                         ,                              ,Full process             ,"Rhodiola will manufacture, conduct trials and sell the vaccine. Early development and manufacturing to be outsourced. May also build production at its subsidiaries. Rhodiola will be able to sell in China, Hong Kong, Macao, and Taiwan, and also in other overseas markets to designed buyers. Number of total doses to be manufactured unclear, but Rhodiola is committed to producing at least 40m doses in 2021.                                                                                                                   ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,China                      ,Upper middle income,Hong Kong                ,High income        ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.reuters.com/article/health-coronavirus-vaccine-russia/chinas-rhodiola-set-to-sell-and-test-russias-sputnik-v-vaccine-idUSKBN27R1NM ; https://www.reuters.com/article/health-coronavirus-vaccine-russia-idUSP8N2HR02H ; https://www.reuters.com/article/health-coronavirus-russia-vaccine-idUSL4N2GS24X
Gamaleya          ,Unidentified                            ,                      ,Serbia               ,Upper middle income,                                              ,4                                               ,2/10/2020                          ,Yes                                        ,Serbia                        ,Phased full process      ,Serbia will start by packaging the vaccine and aims to undertake full process production by the end of 2021. Not clear what manufacturer will be doing this.                                                                                                                                                                                                                                                                                                                                                                               ,"Serbian government pledged to invest in necessary equipment to locally produce the vaccine, but noted worldwide shortages.                                                                                                                                                                                                                                                                               ","Financed by the Serbian government, although details are unavailable.                                                                                                                                                                                                                                                                                                                                                                                                          ",Serbia                     ,Upper middle income,Europe & Central Asia    ,0                  ,Reuters mentions that vaccine could be distributed to the whole of europe. The anticipated 4m doses is part of the first phase of production; deal with Serbian government is for 2m doses.                                                                                                                                                                                                                                                                                                                                                                       ,https://tass.com/world/1254895 ; https://seenews.com/news/serbia-to-start-producing-russias-sputnik-v-vaccine-by-may-20-govt-official-734479 ; https://www.reuters.com/article/us-health-coronavirus-serbia-russia-idUSKBN2AB27Y
Gamaleya          ,Pharco Pharmaceuticals                  ,Privately held        ,Egypt                ,Lower middle income,                                              ,25                                              ,9/1/2020                           ,Yes                                        ,Egypt                         ,Fill-and-finish          ,Initial agreement for a supply of 25m doses was signed in Sep 2020 with a possibility of further collaboration. FT and a local news source report on manufacturing in Egypt as well. Pharco will reportedly fill and finish the doses. But reports also suggest that they don't have enough production capacities                                                                                                                                                                                                                          ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Egypt                      ,Lower middle income,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://atalayar.com/en/content/egypt-produce-russian-covid-19-vaccine ; https://www.ft.com/content/316b77c1-e640-4d53-8dec-547b1b5651d8
Inovio            ,Advaccine Biopharmaceuticals            ,Privately held        ,China                ,Upper middle income,100                                           ,                                                ,1/4/2021                           ,No                                         ,                              ,Full process             ,"A collaboration and licensing agreement. Advaccine will have the exclusive right to develop, manufacture and commercialize INO-4800 within Greater China, inclusive of Mainland China, Hong Kong, Macao, and Taiwan. It is also undertaking clinical trials in China                                                                                                                                                                                                                                                                     ",                                                                                                                                                                                                                                                                                                                                                                                                           ,Advaccine will make to INOVIO an upfront payment of $3.0 million as well as pay an aggregate of $108.0 million upon the achievement of specified development and sales-based milestones for INO-4800 in Greater China. INOVIO will be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within Greater China.                                                                                                             ,China                      ,Upper middle income,Hong Kong                ,High income        ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,http://ir.inovio.com/news-releases/news-releases-details/2021/INOVIO-and-Advaccine-Announce-Exclusive-Partnership-To-Commercialize-COVID-19-DNA-Vaccine-Candidate-INO-4800-in-Greater-China/default.aspx
Inovio            ,Ology Bioservices                       ,Privately held        ,United States        ,High income        ,                                              ,                                                ,3/24/2020                          ,No                                         ,United States                 ,Full process             ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,Tech transfer involved.                                                                                                                                                                                                                                                                                                                                                                                    ,"US Department of Defense (DOD) awarded Ology Bioservices an 11.9m USD contract to coordinate ""with Inovio on DNA technology transfer to rapidly manufacture DNA vaccines."" Intended particularly for US armed services.                                                                                                                                                                                                                                                      ",United States              ,High income        ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.prnewswire.com/news-releases/ology-bioservices-inovio-partner-to-manufacture-covid-19-dna-vaccine-with-11-9-million-department-of-defense-grant-301028626.html
Inovio            ,Thermo Fischer Scientific               ,Publicly traded       ,United States        ,High income        ,100                                           ,                                                ,9/8/2020                           ,No                                         ,                              ,Full process             ,Will provide bulk substance manufacturing and fill-and-finish at its facilities in the US.                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.scienceboard.net/index.aspx?sec=ser&sub=def&pag=dis&ItemID=1298
Inovio            ,Richter-Helm BioLogics GmbH & Co        ,Privately held        ,Germany              ,High income        ,                                              ,                                                ,4/20/2020                          ,No                                         ,                              ,Full process             ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,"Richter-Helm BioLogics is using manufacturing technology developed by VGXI Inc., a wholly owned subsidiary of GeneOne Life Science and Inovio's contract manufacturer for early-stage clinical trial supply, under a license agreement from VGXI. Richter-Helm BioLogics will transfer and rapidly scale up the current (400 L scale) production process for the INO-4800 DNA plasmid from VGXI          ",This manufacturing arrangement is partially funded by a 1.3m USD grant from CEPI.                                                                                                                                                                                                                                                                                                                                                                                                ,                           ,#N/A               ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Expands-Manufacturing-of-COVID-19-DNA-Vaccine-INO-4800-With-New-Funding-from-CEPI/default.aspx
Inovio            ,Kaneka Eurogentec                       ,Publicly traded       ,Japan                ,High income        ,                                              ,                                                ,12/3/2020                          ,No                                         ,                              ,Full process             ,"Will be able to produce ""hundreds of millions of doses"" with the Kaneka Eurogentec facilities in Belgium.                                                                                                                                                                                                                                                                                                                                                                                                                              ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,World                      ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Expands-Global-Manufacturing-Consortium-For-Its-COVID-19-Vaccine-Candidate-INO-4800-With-Addition-of-Kaneka-Eurogentec-S.A/default.aspx
Johnson & Johnson ,Catalent                                ,Publicly traded       ,United States        ,High income        ,                                              ,                                                ,4/29/2020                          ,No                                         ,                              ,Full process             ,"Full manufacturing at New Jersey plant for sale in US, and fill-finish manufacturing at its plant in Italy for the European market.                                                                                                                                                                                                                                                                                                                                                                                                      ",Plans to scale-up capacity with new machines and hiring of approximately 300 additional workers at their US plant.                                                                                                                                                                                                                                                                                         ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,United States              ,High income        ,European Union           ,High income        ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.fiercepharma.com/manufacturing/j-j-touts-covid-vaccine-supply-chain-stability-eyes-plans-for-2022 ; https://www.catalent.com/catalent-news/catalent-signs-agreement-with-johnson-johnson-for-lead-covid-19-vaccine-candidate/
Johnson & Johnson ,Sanofi                                  ,Publicly traded       ,France               ,High income        ,144                                           ,                                                ,2/22/2021                          ,No                                         ,                              ,Full process             ,"144m doses/year, estimated based on reported 12m doses/month capacity. To be produced at facility in France - ""formulate and fill."" Not clear what market resultant vaccine will be sold on.                                                                                                                                                                                                                                                                                                                                           ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.sanofi.com/en/media-room/press-releases/2021/2021-02-22-11-40-00-2179318
Johnson & Johnson ,Merck & Co.                             ,Publicly traded       ,United States        ,High income        ,                                              ,                                                ,3/2/2021                           ,No                                         ,United States                 ,Full process             ,The US arranged for an agreement between J&J and Merck. One Merck facility will be used as fill-and-finish and another will be used for making the drug substance. Appears that these doses are intended primarily to be for the US market. Unclear how many doses will be produced at Merck facilities or when they will be ready to begin producing doses.                                                                                                                                                                               ,Adaptations to facilities                                                                                                                                                                                                                                                                                                                                                                                  ,The US is providing up to 269m USD to support Merck to adapt and make available its facilities for J&J vaccine production.                                                                                                                                                                                                                                                                                                                                                       ,United States              ,High income        ,World                    ,0                  ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.nytimes.com/2021/03/02/us/politics/merck-johnson-johnson-vaccine.html
Johnson & Johnson ,Grand River Aseptic Manufacturing (GRAM),Privately held        ,United States        ,High income        ,                                              ,                                                ,9/25/2020                          ,No                                         ,United States                 ,Fill-and-finish          ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,Completed a 60m USD expansion to their facility in June 2020.                                                                                                                                                                                                                                                                                                                                              ,"Supported by US government. Under a US government contract, GRAM will provide up to 100m doses for the US strategic federal reserve; not clear how this fits into the existing US purchase arrangements for J&J.                                                                                                                                                                                                                                                               ",Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.fiercepharma.com/manufacturing/j-j-touts-covid-vaccine-supply-chain-stability-eyes-plans-for-2022
Johnson & Johnson ,Reig Jofre                              ,Publicly traded       ,Spain                ,High income        ,50                                            ,                                                ,12/15/2020                         ,No                                         ,                              ,Full process             ,"Reig Jofre will provide formulation, filling and packaging of the vaccine for Johnson and Johnson to distribute.                                                                                                                                                                                                                                                                                                                                                                                                                         ",Deal includes tech transfer                                                                                                                                                                                                                                                                                                                                                                                ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.reigjofre.com/en/noticias/item/reig-jofre-announces-technology-transfer-of-the-large-scale-manufacturing-in-spain-for-a-covid-19-vaccine-candidate/ ; https://www.reuters.com/article/us-reig-jofre-johnson-johnson-vaccine-idUSKBN28P0V2
Johnson & Johnson ,Aspen Pharmacare                        ,Publicly traded       ,South Africa         ,Upper middle income,300                                           ,                                                ,11/2/2020                          ,No                                         ,                              ,Full process             ,"J&J will provide capacity to enable Aspen to perform ""formulation, filling, and secondary packaging.""                                                                                                                                                                                                                                                                                                                                                                                                                                  ","The agreement between Aspen and J&J is ""subject to the completion of the relevant technology transfer activities and finalisation of certain commercial manufacturing terms.""                                                                                                                                                                                                                          ",184.2 million USD invested to upgrade facility                                                                                                                                                                                                                                                                                                                                                                                                                                   ,World                      ,0                  ,                         ,#N/A               ,All the produced vaccines will be exported to J&J. The South African govt is trying to secure some of these produced vaccines for local distribution                                                                                                                                                                                                                                                                                                                                                                                                              ,https://www.fiercepharma.com/manufacturing/j-j-touts-covid-vaccine-supply-chain-stability-eyes-plans-for-2022 ; https://www.reuters.com/article/uk-health-coronavirus-aspen-pharmacare-v-idUSKBN29C1V4 ; https://www.reuters.com/article/us-health-coronavirus-aspen-pharmacare/south-africas-aspen-agrees-initial-deal-to-make-jj-vaccine-candidate-idUSKBN27I0N8 ; https://www.aspenpharma.com/2020/11/02/aspen-announces-agreement-with-johnson-johnson-to-manufacture-investigational-covid-19-vaccine-candidate/
Johnson & Johnson ,Emergent BioSolutions                   ,Publicly traded       ,United States        ,High income        ,                                              ,1000                                            ,4/23/2020                          ,No                                         ,                              ,Full process             ,"Will provide manufacturing from molecule to market. After an initial technology transfer agreement in April of 2020 with an estimated value of 135 million USD, a large-scale, five-year contract was signed in July 2020. Contract valued at 480m USD for first two years. Manufacturing capacity of up to 4000L.                                                                                                                                                                                                                       ",Few details on the tech transfer.                                                                                                                                                                                                                                                                                                                                                                          ,Initial technology transfer valued at 135 million USD; later long-term five year contract valued at 480 million USD for first two years.                                                                                                                                                                                                                                                                                                                                         ,World                      ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,"https://www.jnj.com/johnson-johnson-announces-collaboration-to-expand-manufacturing-capabilities-for-its-covid-19-vaccine-candidate-in-support-of-the-companys-goal-to-supply-more-than-one-billion-vaccine-doses-globally ; https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-signs-five-year-agreement-large-scale-drug ; https://www.biospace.com/article/j-and-j-strikes-covid-19-manufacturing-deal-with-emergent-biosolutions/#:~:text=J%26J%20and%20Emergent%20BioSolutions%20Strike%20Manufacturing%20Deal%20for%20COVID%2D19%20Vaccine%20Candidate,-Published%3A%20Apr%2024&text=Late%20Thursday%2C%20the%20two%20companies,of%20the%20potential%20vaccine%20candidate."
Johnson & Johnson ,Grand River Aseptic Manufacturing (GRAM),Privately held        ,United States        ,High income        ,                                              ,100                                             ,9/25/2020                          ,No                                         ,                              ,Fill-and-finish          ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,"The deal ""includes technical transfer and fill and finish manufacture"" in new facilities. Finished a 60m USD expansion to their facility in June 2020.                                                                                                                                                                                                                                                 ",Partially funded through the US government (BARDA) funding.                                                                                                                                                                                                                                                                                                                                                                                                                      ,World                      ,0                  ,                         ,#N/A               ,"In addition to this production for J&, under a US government contract, GRAM will provide up to 100m doses for the US strategic federal reserve at facility in the US. Not clear how this 100m fits into existing US purchase agreements for J&J.                                                                                                                                                                                                                                                                                                                ",https://www.prnewswire.com/news-releases/gram-partners-with-johnson--johnson-on-manufacturing-in-fight-against-covid-19-301137966.html ; https://www.fiercepharma.com/manufacturing/johnson-johnson-signs-michigan-s-grand-river-to-help-covid-19-vaccine-finishing-work
Johnson & Johnson ,Vibalogics                              ,Privately held        ,Germany              ,High income        ,                                              ,                                                ,5/14/2020                          ,No                                         ,                              ,Full process             ,"Vibalogics to produce clinical trial material for J&J vaccine, resulting in production of thousands of doses. Have new equipment capable of ""filling and labelling more than 30,000 vials per batch.""                                                                                                                                                                                                                                                                                                                                  ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://vibalogics.com/vibalogics-announces-collaboration-with-janssens-to-provide-additional-clinical-trial-material-for-covid-19-vaccine-candidate/
Johnson & Johnson ,Biological E                            ,Privately held        ,India                ,Lower middle income,                                              ,600                                             ,8/13/2020                          ,No                                         ,                              ,Full process             ,"A news report in Feb 2021 quoted the managing director of Biological E stating that their were ""targeting 600 million doses for J&J""                                                                                                                                                                                                                                                                                                                                                                                                   ","Limited details on the tech transfer, but the agreement is part of an attempt ""for the creation / enhancement of manufacturing capacities"" for the J&J vaccine candidate. One news report noted that Biological E purchased a 39,000 square foot facility shortly after this arrangement was announced, which could potentially add ""more than 165 million doses to the drugmaker's annual capacity.""",                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.jnj.in/about-jnj/company-statements/statement-on-johnson-johnsons-collaboration-in-india-with-biological-e-to-expand-manufacturing-capabilities-for-its-covid-19-vaccine-candidate ; https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/biological-e-signs-pact-with-jj-for-covid-19-vaccine-technology/articleshow/77522853.cms?from=mdr ; https://www.biologicale.com/news.html ; https://www.firstpost.com/india/biological-e-to-produce-600-mn-doses-of-johnson-johnson-covid-19-vaccine-a-year-9289811.html ; https://www.fiercepharma.com/manufacturing/j-j-touts-covid-vaccine-supply-chain-stability-eyes-plans-for-2022
Moderna           ,Recipharm                               ,Privately held        ,Sweden               ,High income        ,                                              ,                                                ,7/30/2020                          ,No                                         ,                              ,Full process             ,Will provide formulation and fill-and-finish for part of the vaccine supply outside the US. Will be manufatured at Recipharm's facility in France.                                                                                                                                                                                                                                                                                                                                                                                         ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,World                      ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.reuters.com/article/us-health-coronavirus-moderna-recipharm-idUSKBN2941TJ ; https://www.recipharm.com/press/recipharm-and-moderna-finalize-agreement-aseptic-drug-product-manufacturing-and-fill-finish
Moderna           ,"Laboratorios Farmacéuticos Rovi, S.A. ",Publicly traded       ,Spain                ,High income        ,                                              ,                                                ,7/9/2020                           ,No                                         ,                              ,Fill-and-finish          ,"Will provide large-scale commercial fill-and-finish manufacturing. Will support production of ""hundreds of millions of doses of the vaccine candidate intended to principally supply markets outisde the US""                                                                                                                                                                                                                                                                                                                           ","As part of deal, will procure new production line and equipment.                                                                                                                                                                                                                                                                                                                                         ",                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,World                      ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://investors.modernatx.com/news-releases/news-release-details/moderna-and-rovi-announce-collaboration-ous-fill-finish
Moderna           ,Catalent                                ,Publicly traded       ,United States        ,High income        ,                                              ,100                                             ,6/25/2020                          ,No                                         ,                              ,Fill-and-finish          ,Will provide fill and finish for at least 100m doses of vaccine candidate at US facility; may be expanded later for millions more doses.                                                                                                                                                                                                                                                                                                                                                                                                   ,Catalent will hire additional staff to allow for 24/7 staffing to increase capacity.                                                                                                                                                                                                                                                                                                                       ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.catalent.com/catalent-news/moderna-and-catalent-announce-collaboration-for-fill-finish-manufacturing-of-modernas-covid-19-vaccine-candidate/
Moderna           ,CordenPharma                            ,Privately held        ,Germany              ,High income        ,                                              ,                                                ,5/28/2020                          ,No                                         ,                              ,Bulk substance production,"CordenPharma will produce large-scale volumes of the lipid excipients to be used in the Moderna vaccine at sites in the US, Switzerland, and France.                                                                                                                                                                                                                                                                                                                                                                                     ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.cordenpharma.com/CordenPharma_and_Moderna_Extend_Lipid_Supply_Agreement_for_Moderna_Vaccine_mRNA-1273_Against_Novel_Coronavirus_SARS-CoV-2
Moderna           ,Lonza                                   ,Publicly traded       ,Switzerland          ,High income        ,1000                                          ,                                                ,5/1/2020                           ,No                                         ,United States                 ,Full process             ,"A 10 year ""Worldwide Strategic Collaboration"", including establishing manufacturing sites in both US and Switzerland                                                                                                                                                                                                                                                                                                                                                                                                                   ",Technology transfer expected to begin in June 2020                                                                                                                                                                                                                                                                                                                                                         ,Partially funded through the US government (BARDA) funding.                                                                                                                                                                                                                                                                                                                                                                                                                      ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www7.lonza.com/~/media/Files/japan/News/200501_Press_Release__Moderna_Lonza_COVID_FINAL.pdf
Novavax           ,Biologics Manufacturing Centre          ,Government agency     ,Canada               ,High income        ,                                              ,                                                ,2/2/2021                           ,No                                         ,Canada                        ,Full process             ,Canadian government facility to manufacture Novavax in the country.                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Canada                     ,High income        ,                         ,#N/A               ,Not clear how this relates to existing purchase arrangements.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ,https://www.globenewswire.com/news-release/2021/02/02/2168516/0/en/Novavax-Announces-Memorandum-of-Understanding-to-Produce-COVID-19-Vaccine-Made-in-Canada.html
Novavax           ,Takeda                                  ,Publicly traded       ,Japan                ,High income        ,250                                           ,                                                ,8/7/2020                           ,No                                         ,Japan                         ,Full process             ,"Takeda will handle the regulatory approval, production and distribution.                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ",Novavax will license COVID-19 vaccine technology to Takeda for local production and commercialization in Japan. The tech transfer will include Novavax’ proprietary Matrix‑M™ adjuvant.                                                                                                                                                                                                                    ,"Funding for the tech transfer, infrastructure and scaling up to be provided by the Govt of Japan. Novavax will receive payments based on the success of the vaccine.                                                                                                                                                                                                                                                                                                           ",Japan                      ,High income        ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.takeda.com/newsroom/newsreleases/2020/novavax-and-takeda-announce-collaboration-for-novavax-covid-19-vaccine-candidate-in-japan/
Novavax           ,Serum Institute                         ,Publicly traded       ,India                ,Lower middle income,1000                                          ,                                                ,9/15/2020                          ,No                                         ,                              ,Full process             ,"Under an amendment of the existing agreement, Serum Institute will also manufacture the antigen component of the vaccine, suggesting will now be engaged in full process manufacturing.                                                                                                                                                                                                                                                                                                                                                  ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,World                      ,0                  ,India                    ,Lower middle income,Serum Institute has stated that half of the vaccines produced will be reserved for the Indian market. But it is not clear if the govt has purchased these or otherwise secured them.                                                                                                                                                                                                                                                                                                                                                                              ,https://ir.novavax.com/news-releases/news-release-details/novavax-announces-covid-19-vaccine-manufacturing-agreement-serum
Novavax           ,SK bioscience                           ,Privately held        ,South Korea          ,High income        ,                                              ,                                                ,8/13/2020                          ,No                                         ,South Korea                   ,Full process             ,"A development and supply agreement for the antigen component of the vaccine candidate. In February 2021, deal expanded to include a license to manufacture and commercialize the vaccine candidate for sale to the South Korean government.                                                                                                                                                                                                                                                                                              ",Details limited but includes tech transfer                                                                                                                                                                                                                                                                                                                                                                 ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,World                      ,0                  ,South Korea              ,High income        ,"SK Bioscience plans to go public later this year. To be supplied to global markets including the COVAX Facility. ""In addition, the companies have signed a letter of intent with the Republic of Korea’s Ministry of Health and Welfare to work toward broad and equitable access to NVX-CoV2373 for the global market as well as to make the vaccine available in South Korea""                                                                                                                                                                               ",https://ir.novavax.com/news-releases/news-release-details/novavax-and-sk-bioscience-announce-collaboration-novavax-covid
Novavax           ,PolyPeptide Group                       ,Privately held        ,Sweden               ,High income        ,                                              ,                                                ,6/4/2020                           ,No                                         ,                              ,Bulk substance production,Will produce 2 key intermediates in the production of the vaccine candidate.                                                                                                                                                                                                                                                                                                                                                                                                                                                               ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.polypeptide.com/wp-content/uploads/2020/06/Press-Release-PolyPeptide-Novavax-Matrix-Adjuvant_2020-06-04.pdf
Novavax           ,Baxter International Inc                ,Publicly traded       ,United States        ,High income        ,                                              ,                                                ,1/11/2021                          ,No                                         ,                              ,Bulk substance production,Agreement to provide manufacturing services for the vaccine adjuvant. Manufacturing to occur at facility in Germany.                                                                                                                                                                                                                                                                                                                                                                                                                       ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,European Union             ,High income        ,United Kingdom           ,High income        ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.baxter.com/baxter-newsroom/baxter-biopharma-solutions-announces-sterile-manufacturing-agreement-novavax-covid
Novavax           ,Praha Vaccines                          ,Privately held        ,India                ,Lower middle income,1000                                          ,                                                ,5/27/2020                          ,No                                         ,                              ,Full process             ,"Novavax fully acquired Praha Vaccines. The acquisition includes a 150,000-square foot state of the art vaccine and biologics manufacturing facility and other support buildings, along with the existing employees and all related and required infrastructure.                                                                                                                                                                                                                                                                          ",                                                                                                                                                                                                                                                                                                                                                                                                           ,Acquisition of Praha Vaccines for 167 million USD in an all-cash transaction by Novavax. Partially funded by CEPI.                                                                                                                                                                                                                                                                                                                                                               ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://ir.novavax.com/news-releases/news-release-details/novavax-expands-large-scale-global-manufacturing-capacity
Novavax           ,AGC Biologics                           ,Publicly traded       ,Denmark              ,High income        ,                                              ,                                                ,8/18/2020                          ,No                                         ,                              ,Bulk substance production,Manufacturing the adjuvant component of the vaccine candidate at facilities in the US and Denmark.                                                                                                                                                                                                                                                                                                                                                                                                                                         ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.agc.com/en/news/detail/1201206_2814.html
Novavax           ,Biofabri                                ,Privately held        ,Spain                ,High income        ,                                              ,100                                             ,9/16/2020                          ,No                                         ,                              ,Bulk substance production,Biofabri will manufacture the Novavax vaccine antigen.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,European Union             ,High income        ,                         ,#N/A               ,"Based on current EU purchase agreements, this would amount to 100m doses.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       ",https://www.bioga.org/biofabri-del-grupo-zendal-elegida-por-la-farmaceutica-novavax-para-la-produccion-en-europa-de-su-vacuna-contra-el-covid/
Novavax           ,Fujifilm Diosynth Biotechnologies       ,Publicly traded       ,Japan                ,High income        ,180                                           ,                                                ,8/14/2020                          ,Yes                                        ,United Kingdom                ,Bulk substance production,Manufacturing arrangement for one of the vaccine components at sites in the UK and the US. UK site expected to prouduce up to 180m doses/year.                                                                                                                                                                                                                                                                                                                                                                                             ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,United Kingdom             ,High income        ,World                    ,0                  ,Deal with manufacturer and with the UK government. Excess supply above the 60 million produced at the UK factory may be made available to Novavax to sell to other markets.                                                                                                                                                                                                                                                                                                                                                                                       ,https://pharmaphorum.com/news/uk-signs-coronavirus-vaccine-deals-with-jj-and-novavax/; https://www.globenewswire.com/fr/news-release/2020/08/14/2078379/0/en/Novavax-and-UK-Government-Announce-Collaboration-and-Purchase-Agreement-for-Novavax-COVID-19-Vaccine-Candidate.html ; https://s3.amazonaws.com/one.org/vaccine-access-test/ONE_VAT_deal_Novavax_United_Kingdom.pdf
Novavax           ,Endo International                      ,Publicly traded       ,United States        ,High income        ,                                              ,                                                ,9/25/2020                          ,No                                         ,                              ,Full process             ,"Production of ""final drug product"" as well as fill and finish at facility in the US                                                                                                                                                                                                                                                                                                                                                                                                                                                    ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,United States              ,High income        ,                         ,#N/A               ,Initial batches intended for use in Phase 3 trial in the US and fill-finish for commercial distribution in the US.                                                                                                                                                                                                                                                                                                                                                                                                                                                ,https://investor.endo.com/news-releases/news-release-details/endo-announces-fill-finish-manufacturing-and-services-agreement
Pfizer/BioNTech   ,Sanofi                                  ,Publicly traded       ,France               ,High income        ,                                              ,125                                             ,1/27/2021                          ,No                                         ,                              ,Fill-and-finish          ,"Sanofi will provide ""late stage manufacturing"" and fill and packing of the vaccine                                                                                                                                                                                                                                                                                                                                                                                                                                                     ",                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,European Union             ,High income        ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.reuters.com/article/us-health-coronavirus-vaccines-sanofi-idUSKBN29V23Y ; https://www.sanofi.com/en/media-room/press-releases/2021/2021-01-27-07-30-00
Pfizer/BioNTech   ,Siegfried                               ,Publicly traded       ,Switzerland          ,High income        ,                                              ,                                                ,9/14/2020                          ,No                                         ,                              ,Fill-and-finish          ,Intention to begin fill-and-finish at Germany site starting in mid-2021.                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ,Siegfried reported to be investing in dedicated production line and providing special storage capacity.                                                                                                                                                                                                                                                                                                    ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Unspecified                ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.siegfried.ch/siegfried+and+biontech+sign+contract+for+the+aseptic+fill+%2526+finish+of+a+covid-19+vaccine/news-en/5746
Pfizer/BioNTech   ,Delpharm                                ,Privately held        ,France               ,High income        ,                                              ,                                                ,11/23/2020                         ,No                                         ,                              ,Full process             ,Will manufacture at a facility in France.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,                           ,#N/A               ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://pharmacie.ma/index/generate-pdf/article_id/6911
Pfizer/BioNTech   ,Rentschler Biopharma SE                 ,Privately held        ,Germany              ,High income        ,                                              ,                                                ,10/7/2020                          ,No                                         ,                              ,Bulk substance production,Responsible for downstream processing to produce a purified product at facility in Germany.                                                                                                                                                                                                                                                                                                                                                                                                                                                ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,                           ,#N/A               ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.rentschler-biopharma.com/news/press-releases-and-announcements/detail/view/joining-forces-against-sars-cov-2/
Pfizer/BioNTech   ,Novartis                                ,Publicly traded       ,Switzerland          ,High income        ,                                              ,                                                ,1/29/2021                          ,No                                         ,                              ,Fill-and-finish          ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,World                      ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.novartis.com/news/media-releases/novartis-signs-initial-agreement-provide-manufacturing-capacity-pfizer-biontech-covid-19-vaccine
Pfizer/BioNTech   ,Shanghai Fosun Pharmaceutical Group Ltd ,Publicly traded       ,China                ,Upper middle income,                                              ,100                                             ,12/16/2020                         ,No                                         ,                              ,Fill-and-finish          ,"Mixed distribution and manufacturing deal. Fosun will import ingredients and finish the product locally, but specifics are not available                                                                                                                                                                                                                                                                                                                                                                                                 ",                                                                                                                                                                                                                                                                                                                                                                                                           ,"607.6m USD estimated total. Fosun paid an estimated 135 million EUR for exclusive commercialization rights on the Chinese mainland, Hong Kong, Macao, and Taiwan. Fosun will be entitled to 60% of gross profits from vaccines it makes from imported ingredients, and 65% of profits from sales of doses imported ready to use. Will pay 303.80 million USD for first 50 million doses supplied to Fosun; this  number used to calculate total price based on number of doses.",China                      ,Upper middle income,Hong Kong                ,High income        ,"Exclusive commercialization rights with Fosun Pharma for China, Hong Kong, Macao, and Taiwain. \                                                                                                                                                                                                                                                                                                                                                                                                                                                                ",https://asia.nikkei.com/Spotlight/Coronavirus/Fosun-to-import-100m-doses-of-BioNTech-vaccine-into-China; https://www.reuters.com/article/us-health-coronavirus-biontech-fosunphar-idUSKBN25N21X ; https://uk.reuters.com/article/us-health-coronavirus-vaccine-biontech/shanghai-fosun-pharma-sinopharm-group-sign-deal-to-supply-biontech-coronavirus-vaccine-candidate-idUKKBN25Y1BC ; https://asia.nikkei.com/Spotlight/Caixin/China-s-Fosun-to-import-7.2m-doses-of-BioNTech-Pfizer-COVID-vaccine
Sinopharm/Beijing ,BCHT Bioteknologi Indonesia             ,                      ,Indonesia            ,Upper middle income,                                              ,                                                ,8/25/2020                          ,No                                         ,                              ,                         ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,                           ,#N/A               ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://asia.nikkei.com/Spotlight/Coronavirus/Indonesia-teams-with-China-s-Sinovac-for-COVID-vaccine
Sinovac           ,Pharmaniaga Berhad                      ,Publicly traded       ,Malaysia             ,Upper middle income,                                              ,14                                              ,1/11/2021                          ,Yes                                        ,Malaysia                      ,Fill-and-finish          ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                           ,Malaysia                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ,Upper middle income        ,0                  ,#N/A                     ,0                  ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://www.reuters.com/article/us-health-coronavirus-malaysia-vaccines/malaysia-secures-18-4-million-doses-of-russian-chinese-covid-19-vaccines-idUSKBN29V11H; https://www.reuters.com/article/health-coronavirus-malaysia/malaysia-buys-astrazeneca-covid-19-vaccines-seeks-more-from-china-russia-idUSKBN28W09K ; https://www.reuters.com/article/us-health-coronavirus-malaysia-sinovac-idUSKBN29H0M5
Sinovac           ,Bio Farma                               ,State-owned enterprise,Indonesia            ,Upper middle income,250                                           ,                                                ,8/25/2020                          ,Yes                                        ,Indonesia                     ,Full process             ,"Phase 3 trial site for Sinovac and recipient of tech transfer for local manufacturing. Plans that Bio Farma will be able to increase its manufacturing capacity to 250 million doses by end of the year, from ~100 million doses right now. PT Bio Farma has stated that the vaccines will be sold for approximately 13.50 USD/dose.                                                                                                                                                                                                     ","Sinovac will provide Bio Farma with the technical know-how to be able to produce the vaccine from raw materials (provided by Sinovac). Part of the transfer is occuring through a partnership with the UAE's G42 Healthcare Holdings (which has also run the UAE clinical trials) for R&D, marketing, and distribution of the vaccine.                                                                   ",                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Indonesia                  ,Upper middle income,                         ,#N/A               ,"[There has been some suggestion that the 'raw materials' includes the antigen but it is unclear what that means, given that the Sinovac vaccine is a heat-inactivated virus.] Sinovac is separately sending smaller amounts of completed vaccine to Indonesia, but after the tech transfer, it is assumed that Bio Farma will be the sole provider of the vaccine in Indonesia. A first transfer of materials for 50m doses is expected between November 2020-March 2021; additional for 210m doses in rest of 2021. Poduction expected to start in January 2021",https://asia.nikkei.com/Spotlight/Coronavirus/Indonesia-teams-with-China-s-Sinovac-for-COVID-vaccine ; https://www.channelnewsasia.com/news/asia/indonesia-covid-19-vaccines-sinovac-china-1-2-million-13769352 ; https://voinews.id/index.php/component/k2/item/8763-sinovac-bio-farma-begins-production-technology-transfer-for-covid-19-vaccine ; https://www.biospace.com/article/releases/sinovac-signs-agreement-with-bio-farma-indonesia-for-covid-19-vaccine-cooperation/
Sinovac           ,Butantan Institute                      ,Government agency     ,Brazil               ,Upper middle income,                                              ,20                                              ,2/5/2021                           ,Yes                                        ,Brazil                        ,Fill-and-finish          ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Brazil                     ,Upper middle income,                         ,#N/A               ,This is separate from the original agreement and is specifically with the Sao Paolo state government.                                                                                                                                                                                                                                                                                                                                                                                                                                                             ,https://www1.folha.uol.com.br/equilibrioesaude/2021/02/butantan-negocia-compra-de-mais-20-milhoes-de-doses-da-coronavac-diz-doria.shtml
Sinovac           ,Butantan Institute                      ,Government agency     ,Brazil               ,Upper middle income,100                                           ,                                                ,6/11/2020                          ,Yes                                        ,Yes                           ,Fill-and-finish          ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           ,"Details on tech transfer are unclear on other sources, except one which mentions that the agreement between Sinovac and Butantan includes transfer of technology. The agreement is also through the Sao Paulo state government and not the federal Brazilian govt                                                                                                                                        ",                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,Brazil                     ,Upper middle income,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://agenciabrasil.ebc.com.br/en/saude/noticia/2020-12/brazilian-institute-start-production-vaccine-coronavac ; https://www.biospace.com/article/releases/sinovac-and-butantan-join-efforts-to-advance-the-clinical-development-of-an-inactivated-vaccine-for-covid-19-to-phase-iii/ ; https://www.gov.br/saude/pt-br/assuntos/noticias/ministerio-da-saude-confirma-compra-de-mais-54-milhoes-de-doses-coronavac; https://www.bbc.com/news/world-latin-america-54619730; https://www.reuters.com/article/idUSL1N2GT1HV
Vaxart            ,"Kindred Biosciences, Inc              ",Publicly traded       ,United States        ,High income        ,                                              ,                                                ,10/7/2020                          ,No                                         ,                              ,Full process             ,Will be manufactured at two facilities in the US. One of the facilities has a 2000L manufacturing scale.                                                                                                                                                                                                                                                                                                                                                                                                                                   ,                                                                                                                                                                                                                                                                                                                                                                                                           ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 ,World                      ,0                  ,                         ,#N/A               ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  ,https://kindredbio.com/frontpage/kindred-biosciences-announces-expansion-of-manufacturing-agreement-with-vaxart-for-covid-19-and-other-vaccine-candidates/
